Difference between revisions of "Neuroendocrine carcinoma"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
Warner-admin (talk | contribs) m (Text replacement - "==[https://www.nccn.org/ NCCN]==" to "==NCCN==") |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
| − | {{#lst: | + | {{#lst:Editorial board transclusions|endo}} |
| + | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
| + | |- | ||
| + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> | ||
| + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | ||
| + | |} | ||
Note: these are regimens tested in histology-specific populations, please see the '''[[Neuroendocrine tumor|main NET page]]''' for other regimens. | Note: these are regimens tested in histology-specific populations, please see the '''[[Neuroendocrine tumor|main NET page]]''' for other regimens. | ||
| + | {{TOC limit|limit=3}} | ||
| + | =Guidelines= | ||
| + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
| + | ==NCCN== | ||
| + | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448 NCCN Guidelines - Neuroendocrine and Adrenal Tumors]''. | ||
=Advanced disease, all lines of therapy= | =Advanced disease, all lines of therapy= | ||
==Cisplatin & Etoposide (EP) {{#subobject:ec90cd|Regimen=1}}== | ==Cisplatin & Etoposide (EP) {{#subobject:ec90cd|Regimen=1}}== | ||
| Line 60: | Line 70: | ||
[[Category:Neuroendocrine carcinoma regimens]] | [[Category:Neuroendocrine carcinoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
| − | |||
[[Category:Neuroendocrine tumors]] | [[Category:Neuroendocrine tumors]] | ||
Latest revision as of 11:34, 13 May 2024
| Section editor | |
|---|---|
| Unfilled If you are interested in this role, please contact us at [email protected]. | |
2 regimens on this page
2 variants on this page
|
Note: these are regimens tested in histology-specific populations, please see the main NET page for other regimens.
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Neuroendocrine and Adrenal Tumors.
Advanced disease, all lines of therapy
Cisplatin & Etoposide (EP)
EP: Etoposide and Platinol (Cisplatin)
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Morizane et al. 2022 (TOPIC-NEC) | 2014-08-08 to 2020-03-06 | Phase 3 (E-switch-ic) | IP | Did not meet primary endpoint of OS |
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV once on day 1
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 3
21-day cycles
References
- TOPIC-NEC: Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. link to original article link to PMC article contains dosing details in manuscript PubMed UMIN000014795
Cisplatin & Irinotecan (IC)
IP: Irinotecan, Platinol (Cisplatin)
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Morizane et al. 2022 (TOPIC-NEC) | 2014-08-08 to 2020-03-06 | Phase 3 (E-switch-ic) | EP | Did not meet primary endpoint of OS |
Chemotherapy
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Irinotecan (Camptosar) 60 mg/m2 IV once per day on days 1, 8, 15
28-day cycles
References
- TOPIC-NEC: Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. link to original article link to PMC article contains dosing details in manuscript PubMed UMIN000014795